Display options
Cite
Zhang J, Deng X. Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes. Exp Ther Med. 2017;13(3):1074-1080doi: 10.3892/etm.2017.4058.
Zhang, J., & Deng, X. (2017). Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes. Experimental and therapeutic medicine, 13(3), 1074-1080. https://doi.org/10.3892/etm.2017.4058
Zhang, Jingliang, and Deng, Xinlian. "Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes." Experimental and therapeutic medicine vol. 13,3 (2017): 1074-1080. doi: https://doi.org/10.3892/etm.2017.4058
Zhang J, Deng X. Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes. Exp Ther Med. 2017 Mar;13(3):1074-1080. doi: 10.3892/etm.2017.4058. Epub 2017 Jan 18. PMID: 28450945; PMCID: PMC5403393.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Mar;13(3):1074-1080. doi: 10.3892/etm.2017.4058. Epub 2017 Jan 18.

Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes.

Experimental and therapeutic medicine

Jingliang Zhang, Xinlian Deng

Affiliations

  1. Department of Pain, Yidu Central Hospital of Weifang Affiliated to Weifang Medical College, Weifang, Shandong 262500, P.R. China.

PMID: 28450945 PMCID: PMC5403393 DOI: 10.3892/etm.2017.4058

Abstract

The pain induced by local acute inflammation results in mild to severe discomfort, in addition to the possibility of physiological dysfunction and psychiatric disorders, such as sleep disorders and depression. However, the pathogenesis of pain is yet to be fully elucidated. In the present study, the effects of bupivacaine were explored in rat models inflammatory pain in order to investigate the anti-pain mechanism of bupivacaine. Complete Freund's adjuvant (CFA) was injected into the right rear foot of the rats to establish a model of transient inflammation-induced pain. Rats were randomly divided into four groups (n=8): CFA, CFA plus bupivacaine, CFA plus saline and untreated. The mechanical withdrawal threshold (MWT) of the rats was detected prior to and following CFA injection, and the results demonstrated that the MWT in the right rear foot significantly decreased from the 1st day of CFA injection (P<0.01; n=8), as compared with the untreated controls. Bupivacaine treatment was demonstrated to significantly increase the MWT of rats treated with CFA stimulation, as compared with the CFA group (P<0.01). Rotarod testing was performed to assess the motor activity of the rats, and the results demonstrated no significant differences among the four groups (P>0.05). Furthermore, the respective body weights of the rats were determined every two days before and after CFA injection, and no significant differences were detected among the four groups (P>0.05). Western blot analysis was performed to analyze expression levels of IκB and nuclear factor (NF)-κB, and the results demonstrated that bupivacaine increased the expression of IκB and decreased the expression levels of NF-κB, as compared with the rats with CFA-induced inflammatory responses, suggesting that bupivacaine inhibited NF-κB activation in the dorsal horn of the lumbar spinal cord of the model rats. Furthermore, reverse transcription-quantitative polymerase chain reaction analysis was performed to analyze the expression levels of inflammatory cytokines, which demonstrated that bupivacaine significantly inhibited the expression of TNF-α, IL-1β and IL-6, as compared with the untreated group (P<0.01). Moreover, bupivacaine treatment significantly decreased the expression of spinal microglial marker OX42 and astrocyte marker-glial fibrillary acidic protein, as compared with the rats in the CFA group (P<0.01). The present findings demonstrated that treatment with bupivacaine significantly decreased the activation of microglia and astrocytes in rat models of inflammatory pain. Therefore, the present results may provide clarification of the pathogenesis and mechanism of inflammation-induced pain and may provide novel therapeutic strategies for the clinical treatment of pain.

Keywords: bupivacaine; glial fibrillary acidic protein; inflammatory cytokines; inflammatory pain; nuclear factor-κB; ox42

References

  1. Ann N Y Acad Sci. 2002 Jun;966:343-54 - PubMed
  2. Genes Brain Behav. 2013 Oct;12(7):705-13 - PubMed
  3. J Clin Invest. 2008 Mar;118(3):1065-73 - PubMed
  4. Methods. 2001 Dec;25(4):402-8 - PubMed
  5. Neurobiol Dis. 2014 Nov;71:159-68 - PubMed
  6. Curr Opin Anaesthesiol. 2011 Aug;24(4):400-7 - PubMed
  7. Mol Interv. 2002 Feb;2(1):22-35 - PubMed
  8. J Clin Anesth. 2013 Feb;25(1):20-7 - PubMed
  9. Neurology. 2015 Mar 3;84(9):888-94 - PubMed
  10. Brain Res. 2009 Jun 18;1276:83-90 - PubMed
  11. Eur J Pharmacol. 2011 Sep 30;667(1-3):215-21 - PubMed
  12. Spine (Phila Pa 1976). 2004 May 15;29(10):1077-81 - PubMed
  13. AACN Clin Issues. 2000 May;11(2):168-78 - PubMed
  14. Mol Pain. 2010 Nov 08;6:77 - PubMed
  15. Anesth Analg. 2008 Nov;107(5):1587-91 - PubMed
  16. IET Syst Biol. 2009 Sep;3(5):356-67 - PubMed
  17. Pain. 2013 Jun;154(6):864-73 - PubMed
  18. Anesth Pain Med. 2011 Jul;1(1):15-9 - PubMed
  19. Neurochem Int. 2015 Mar;82:1-9 - PubMed
  20. Altern Ther Health Med. 2014 Winter;20 Suppl 1:32-7 - PubMed
  21. Curr Pharm Des. 2015;21(7):831-9 - PubMed
  22. Mol Pain. 2009 Sep 22;5:53 - PubMed
  23. Methods Mol Biol. 2015 ;1280:15-24 - PubMed
  24. Brain Behav Immun. 2010 May;24(4):652-9 - PubMed
  25. FEBS Lett. 2007 Dec 11;581(29):5549-54 - PubMed
  26. Res Vet Sci. 2010 Feb;88(1):159-65 - PubMed
  27. J Neuroinflammation. 2015 Jan 20;12 :10 - PubMed
  28. PLoS One. 2013 Dec 11;8(12):e82930 - PubMed
  29. Mol Pharmacol. 2009 May;75(5):1014-20 - PubMed
  30. Anesth Analg. 2015 Jun;120(6):1226-34 - PubMed
  31. Brain Res Rev. 2006 Aug;51(2):240-64 - PubMed
  32. Neurosci Lett. 2015 Apr 10;592:99-106 - PubMed
  33. EMBO J. 2007 Apr 4;26(7):1794-805 - PubMed
  34. Pain. 2015 Apr;156(4):597-608 - PubMed
  35. Ann Neurol. 2008 Sep;64(3):274-83 - PubMed
  36. Mol Pain. 2012 Jun 15;8:43 - PubMed
  37. Anesthesiology. 1997 Jun;86(6):1359-66; discussion 8A - PubMed
  38. Brain Behav Immun. 2013 Mar;30 Suppl:S58-67 - PubMed
  39. J Biol Chem. 2003 Sep 26;278(39):37297-305 - PubMed

Publication Types